scholarly journals Antitumor effects of different administration sequences of cisplatin and Endostar on Lewis lung carcinoma

2014 ◽  
Vol 9 (2) ◽  
pp. 822-828 ◽  
Author(s):  
JUAN FAN ◽  
JIANGRONG DU ◽  
JINGBO WU ◽  
SHAOZHI FU ◽  
DEFENG HU ◽  
...  
Keyword(s):  
Lung Carcinoma ◽  
Lewis Lung Carcinoma ◽  
Lewis Lung ◽  
Antitumor Effects

scholarly journals Effect of Micelle-Incorporated Cisplatin With Sizes Ranging From 8 to 40 nm for the Therapy of Lewis Lung Carcinoma

2021 ◽  
Vol 12 ◽  
Author(s):  
Zhicheng Wang ◽  
Yumin Li ◽  
Tong Zhang ◽  
Hongxia Li ◽  
Zhao Yang ◽  
...  
Keyword(s):  
Block Copolymers ◽  
Lung Carcinoma ◽  
Lewis Lung Carcinoma ◽  
Drug Loading ◽  
Complexation Reaction ◽  
Lewis Lung ◽  
Antitumor Effects ◽  
Lung Carcinoma Cells

Insufficient transport of therapeutic cargo into tumor bed is a bottleneck in cancer nanomedicine. Block copolymers are promising carriers with smaller particle size by ratio modification. Here, we constructed cisplatin nanoparticles with sizes ranging from 8 to 40 nm to study the permeability and therapy of Lewis lung carcinoma. We synthesized methoxypoly(ethylene glycol)2000-block poly(L-glutamic acid sodium salt)1979 loading cisplatin through complexation reaction. The cisplatin nanomedicine has high drug loading and encapsulation efficiency. In vitro data demonstrated that cisplatin nanoparticles had equivalent growth-inhibiting effects on Lewis lung carcinoma cells compared to free cisplatin. In vivo evidences showed cisplatin nanoparticles had superior antitumor effects on the Lewis lung carcinoma mouse model with no obvious side effects. All results indicated that optimizing the ratio of block copolymers to obtain smaller sized nanomedicine could act as a promising strategy for overcoming the inadequate accumulation in poorly vascularized tumors.

scholarly journals Nanoliposomal L-Asparaginase and Its Antitumor Activities in Lewis Lung Carcinoma Tumor-Induced BALB/c Mice

2019 ◽  
Vol 2019 ◽  
pp. 1-8 ◽  
Author(s):  
Thi Thao Do ◽  
Thi Phuong Do ◽  
Thi Nga Nguyen ◽  
Thi Cuc Nguyen ◽  
Thi Thu Phuong Vu ◽  
...  
Keyword(s):  
Side Effects ◽  
Antitumor Activity ◽  
Cytotoxic Activity ◽  
Lung Carcinoma ◽  
Lewis Lung Carcinoma ◽  
Lewis Lung ◽  
Antitumor Activities ◽  
Antitumor Effects ◽  
Carcinoma Tumor

Although L-Asparaginase (L-ASP) is an effective chemotherapeutic agent, it has side effects such as fever, skin rashes, chills, anaphylaxis, and severe allergic reactions. Moreover, the short half-life of L-ASP reduces its antitumor activity. To reduce its side effects and broaden its pharmaceutical applications, L-ASP obtained from Pectobacterium carotovorum was subjected to liposomal conjugation. The enzyme was then loaded into liposomes using the hydrated thin-film method. The in vitro cytotoxic activity of liposomal L-ASP was evaluated with the MTT assay using cancerous cell lines, and its antitumor effects were examined in Lewis lung carcinoma (LLC) tumorized mice. The average size of the liposomes containing purified L-asparagine was 93.03 ± 0.49 nm. They had a zeta potential of –15.45 ± 6.72 mV, polydispersity index of 0.22 ± 0.02, and encapsulation efficiency of 53.99 ± 5.44%. The in vitro cytotoxic activity of liposomal L-ASP was less effective against LLC, MCF-7 (human breast carcinoma), HepG2 (human hepatocellular carcinoma), SK-LU-1 (human lung carcinoma), and NTERA-2 (pluripotent human embryonic carcinoma) cells than that of free L-ASP. However, the antitumor activity of liposomal L-ASP was significantly greater than that of untrapped L-ASP at the same doses (6 UI/mouse) in terms of tumor size (6309.11 ± 414.06 mm3) and life span (35.00 ± 1.12 days). This is the first time the antitumor activities of PEGylated nanoliposomal L-ASP have been assessed in LLC carcinoma tumor-induced BALB/c mice and showed significantly improved pharmacological properties compared to those of free L-ASP (P<0.05). Thus, nanoliposomal L-ASP should be considered for its widening applications against carcinoma tumors.

scholarly journals Antitumor effects of Endostar(rh-endostatin) combined with gemcitabine in different administration sequences to treat Lewis lung carcinoma

2019 ◽  
Vol Volume 11 ◽  
pp. 3469-3479 ◽  
Author(s):  
Yuan Li ◽  
Pan Huang ◽  
Hongju Peng ◽  
Hongcheng Yue ◽  
Min Wu ◽  
...  
Keyword(s):  
Lung Carcinoma ◽  
Lewis Lung Carcinoma ◽  
Lewis Lung ◽  
Antitumor Effects

Synergistic antitumor effects of 131I-LC-1 IgM and IL-12 vaccine on Lewis lung carcinoma

2010 ◽  
Vol 10 (3) ◽  
pp. 284-289 ◽  
Author(s):  
Xiao Ling Yin ◽  
Xuexian Yan ◽  
Ming Wen ◽  
Zhi Ping Peng ◽  
Shao Lin Li
Keyword(s):  
Lung Carcinoma ◽  
Lewis Lung Carcinoma ◽  
Lewis Lung ◽  
Antitumor Effects

Effect of a nos inhibitor, t1023, in combination with γ-irradiation and cyclophosphamide on growth and metastasis of Lewis lung carcinoma

2019 ◽  
pp. 105-109
Author(s):  
М.В. Филимонова ◽  
В.М. Макарчук ◽  
Л.И. Шевченко ◽  
А.С. Филимонов
Keyword(s):  
Tumor Growth ◽  
Lung Carcinoma ◽  
Lewis Lung Carcinoma ◽  
Statistical Significance ◽  
Combined Treatment ◽  
Lewis Lung ◽  
Γ Irradiation ◽  
Antitumor Effects ◽  
Nos Inhibitors ◽  
Nos Inhibitor

Цель работы - изучение антинеопластических эффектов при комбинированном воздействии ингибитора NOS Т1023 с γ-излучением и циклофосфамидом. Методика. В работе использован штамм эпидермоидной карциномы легких Льюиса. Выполнено 2 независимых эксперимента: в одном изучали антинеопластические эффекты при раздельном и комбинированном воздействии Т1023 и γ-излучения, в другом - при раздельном и комбинированном воздействии Т1023 и циклофосфамида. Особям 1-й опытной группы в обоих экспериментах с 7-х по 20-е сут роста карциномы ежедневно вводили соединение Т1023 в дозе 60 мг/кг внутрибрюшинно. В первом эксперименте животные 2-й опытной группы на 7-е сут роста неоплазии получали сеанс облучения (доза 5 Гр). Во втором эксперименте животным этой группы на 7-е сут роста неоплазии вводили однократно внутрибрюшинно циклофосфамид в дозе 100 мг/кг в виде 1,0% раствора фармакопейного препарата на основе 0,9% раствора натрия хлорида. Животным 3-й опытной группы в обоих экспериментах проводили соответствующие комбинированные воздействия по этим же схемам и в таких же дозах. Первое введение Т1023 на 7-е сут роста карциномы этим животным проводили через 4 ч после облучения или введения циклофосфамида. Влияние на рост опухоли оценивали по межгрупповым различиям объемов опухолевых узлов, длительности задержки роста и индексу торможения роста опухоли. Влияние на активность метастазирования карциномы оценивали по межгрупповым различиям числа легочных метастазов на 21-е сут роста опухоли и индексу ингибирования метастазирования. Статистическую оценку значимости межгрупповых различий количественных показателей проводили с помощью дисперсионного анализа Краскела-Уоллиса с применением Q-критерия Данна. Результаты. Показано, что воздействие Т1023, как в комбинации с γ-излучением, так и в комбинации с циклофосфамидом, сопровождается статистически значимым подавлением роста и метастазирования карциномы легких Льюис. При этом антинеопластические эффекты обоих комбинированных воздействий соответствовали аддитивному противоопухолевому и антиметастатическому действию ингибитора NOS, γ-излучения и циклофосфамида. Заключение. Полученные результаты отражают способность ингибиторов NOS повышать эффективность радио- и химиотерапии злокачественных новообразований, что свидетельствуют о перспективности дальнейшей разработки препаратов типа соединения Т1023. The aim was to study antineoplastic effects of a NOS inhibitor, T1023, in combination with γ-irradiation and cyclophosphamide. Methods. Epidermoid Lewis lung carcinoma (LLC) was used as a tumor model. Two independent experiments were performed. In the first experiment, antitumor effects of T1023 and γ-irradiation were studied individually and combined. In the second experiment, antitumor effects of T1023 and cyclophosphamide were studied individually and combined. In both experiments, mice from the first experimental group were daily injected with T1023 60 mg/kg from day 7 to 20. In the first experiment, animals of the second group were treated with γ-irradiation at 5 Gy on day 7 of tumor growth. In the second experiment, mice of the second group were injected with cyclophosphamide 100 mg/kg on day 7 of tumor growth. In both experiments, mice of the third group received a respective combined treatment according to the protocols described above. The first injection of T1023 was performed on day 7 after tumor transplantation at 4 hours after the irradiation or cyclophosphamide treatment. Antitumor effects were assessed by comparing the tumor size, duration of tumor growth delay, and the index of tumor growth inhibition in control and experimental groups. The effect of treatments on metastatic activity of carcinoma was evaluated by the intergroup difference in number of pulmonary metastases inhibition index on day 21 of tumor growth. Statistical significance was determined using the Kruskal-Wallis dispersion analysis with the Dunn Q-test. Results of the study showed that the T1023 treatment both in combination with γ-irradiation and with cyclophosphamide was associated with a significantly greater inhibition of tumor growth and metastasis. The antineoplastic effect of both combinations was consistent with the additive antitumor and antimetastatic effect of the NOS inhibitor, γ-radiation, and cyclophosphamide. Conclusion. The study showed the ability of NOS inhibitors to enhance the effectiveness of radio- and chemotherapy for malignant tumors and suggested a promising outlook for further development of T1023.

Antitumor Effects of JAK3 Inhibitor on the Model of Transplantable Lewis Lung Carcinoma and Mechanisms of Their Development

2016 ◽  
Vol 161 (3) ◽  
pp. 367-370 ◽  
Author(s):  
G. N. Zyuz’kov ◽  
E. N. Amosova ◽  
A. V. Chaikovskii ◽  
L. A. Miroshnichenko ◽  
E. V. Udut ◽  
...  
Keyword(s):  
Lung Carcinoma ◽  
Lewis Lung Carcinoma ◽  
Lewis Lung ◽  
Antitumor Effects ◽  
Jak3 Inhibitor
Sign in / Sign up

Export Citation Format

Share Document